NeraCare’s Immunoprint helps in identifying early-stage melanoma patients who are at high risk of relapse and death. Credit: Nephron / commons.wikimedia.org.

Dutch diagnostics corporation SkylineDx and German company NeraCare have entered a strategic partnership to advance precision medicine for early-stage melanoma.

The collaboration will work on the co-development of a test to help life science companies bring therapies for melanoma to market.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It includes an exclusive agreement for the co-development and licensing of NeraCare’s Immunoprint proteomic test which identifies early-stage melanoma patients who are at high risk of relapse and death.

Under the partnership, both companies will use SkylineDx’s global network, discovery and experience in validation to accelerate the development of Immunoprint. 

SkylineDx chief scientific officer Jvalini Dwarkasing said: “This partnership marks a significant milestone for SkylineDx as the world continues to move forward on personalised care and away from one-size-fits-all approaches to medicine.

See Also:

“The team at NeraCare has made great progress in melanoma-risk stratification. Through this collaboration, we anticipate to accelerate the development of precision diagnostics and treatment for patients with this life-threatening disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Immunoprint test will allow the drug innovators to include only the patients who meet the specified criteria in their trial.

This will help in improving the trial’s success and rapidly bringing the drug to market.

The companies will present the archival validation data regarding the impact of Immunoprint for patient selection at the ongoing European Association of Dermato-Oncology congress being held in Rome, Italy.

NeraCare Co-Founders Daniel von Janowski and Friedrich Ackermann said: “We are thrilled to partner with SkylineDx as they have a proven research and development track record and success in bringing innovative diagnostic solutions to market.”